Weekly odanacatib treatment for 52 weeks increased BMD at the lumbar spine and at all hip sites in a dose-dependent manner and was well tolerated in Japanese patients with osteoporosis.
The aim of the study was to assess the efficacy/safety of once- (100 mg q.d.) or twice-daily (50 mg b.i.d.) sitagliptin 100 mg/day in Japanese patients with type 2 diabetes (T2DM). In this randomized, double-blind study, 80 patients with inadequate glycemic control (HbA1c=6.5-10%; FPG =15.0 mmol/l) were randomized equally to sitagliptin 100 mg q.d., 50 mg b.i.d. or placebo for 4 weeks. At baseline and Week 4, frequent blood sampling was performed to assess 24-h weighted mean glucose (24-h WMG). Patients in the efficacy analyses (n=76) had a mean baseline HbA1c of 7.7%. At Week 4, least-squares mean changes in 24-h WMG were reduced with sitagliptin 100 mg q.d. and 50 mg b.i.d. versus placebo (-1.9, -1.6, and -0.5 mmol/l, respectively; p<0.001). Sitagliptin significantly improved FPG and 2-h PPG compared to placebo. No significant differences in 24-h WMG, FPG, or 2-h PPG were observed between the sitagliptin groups. Sitagliptin was well tolerated with no hypoglycemic events. In Japanese patients with T2DM, sitagliptin 100 mg/day provided substantial and continuous 24-h glucose-lowering over 4 weeks. The same glucose-lowering efficacy and tolerability were observed with sitagliptin 100 mg/day whether administered as a once-daily or twice-daily regimen. These results support a once-daily dosing regimen in Japanese patients with T2DM.
Differences have been found in the expression of c-met proIncreased levels of expression of hepatocyte growth tooncogene product (c-met pp) and HGF in liver tissue. In factor (HGF) and its specific receptor c-met have been normal human liver, HGF has been detected in bile duct shown in the liver of several benign and malignant paepithelia and in endothelial cells of both the central-lobular thologies, both in experimental models and humans. We vein and portal tracts vessels, [8][9][10]12 whereas c-met pp has been investigated by immunohistochemistry the presence of identified only in normal mature hepatocytes. 6 In rat liver, both HGF and c-met protooncogene product (c-met pp)HGF has also been found to be expressed in Kupffer cells in 20 hepatocellular carcinomas (HCCs), 5 focal nodular and Ito cells, 9-13 and c-met pp in the ''facultative stem cells'' hyperplasias (FNHs), 4 cases of fulminant hepatitis (FH), often referred to as oval cells (OCs). 13 The latter are considand 1 case of regenerated liver. The c-met protooncogene ered to be bipotential progenitor cells, because they can difproduct was expressed in all cases with marked overexferentiate either toward bile duct epithelial cells or hepatopression in the HCCs and in ductular metaplasia. HGF cytes. 14 Small single cells with an oval nucleus, scanty was detected in the Ito cells of all cases and in neoplastic cytoplasm, and ultrastructural and phenotypic features simihepatocytes of 9 of 20 HCCs (45%). The proliferative inlar to rat OCs have recently been identified in human regendex of each lesion was evaluated by means of the polyerating liver. 15 These cells react with the rat OC-specific clonal antibody anti-cyclin A. When the level of expresmonoclonal antibody (MoAb), OV-6. 16 sion of HGF and c-met protooncogene product with the Increases in c-met pp expression have been reported in percentage of cyclin A / nuclei were compared, the closhepatocytes of many benign and malignant human liver tisest relationship was between c-met protooncogene prodsues. [17][18][19] Furthermore, in experimental hepatic regeneration, uct and cyclin A. In 11 of 20 HCCs (55%), there was no the overexpression of c-met pp in OCs matches that of HGF correlation between HGF positivity and cyclin A. This in Ito cells. 13 To the best of our knowledge, however, the seems to suggest that, independently of the levels of naexpression of HGF and its specific c-met pp receptor has not tive liver HGF, c-met protooncogene product is the most yet been studied extensively in different pathological human active modulator of liver cell proliferation. (HEPATOLOGY liver conditions, although conflicting results have been re-1996;24:60-64.) ported in a small series of hepatomas. 20 Identification of the mechanism that modulates the proliferation of OCs could Hepatocyte growth factor (HGF) is believed to be the most benefit our understanding of liver regeneration and the early important mitogen for hepatocytes in vitro, and the humoral steps of liver carcinogenesis. mediator of liver regeneratio...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.